This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will provide $787,267 to Yale University to conduct research aimed at understanding the role of cholesterol biosynthetic intermediates and derivatives in regulating macrophage function and inflammation in atherosclerosis. The research will utilize novel animal models and cutting-edge genomics and metabolomics techniques to evaluate the potential therapeutic efficacy of increasing desmosterol levels in macrophages for treating cardiometabolic diseases. This 4-year project, with a start date of January 1, 2025 and an ultimate completion date of November 30, 2028, aligns with the program's objective to advance knowledge about heart diseases, their mechanisms, risk factors, and potential interventions through rigorous scientific exploration.
Generated 1/28/25, 7:17 AM